prabotulinumtoxinA
Pre-clinicalActive 0 views this week 0 watching💤 Quiet
Interest: 20/100
20
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Glabellar Frown Lines
Conditions
Glabellar Frown Lines
Trial Timeline
Mar 15, 2023 → Jan 1, 2026
NCT ID
NCT05481931About prabotulinumtoxinA
prabotulinumtoxinA is a pre-clinical stage product being developed by Evolus for Glabellar Frown Lines. The current trial status is active. This product is registered under clinical trial identifier NCT05481931. Target conditions include Glabellar Frown Lines.
What happened to similar drugs?
0 of 11 similar drugs in Glabellar Frown Lines were approved
Approved (0) Terminated (0) Active (11)
Hype Score Breakdown
Clinical
3
Activity
12
Company
5
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05481931 | Pre-clinical | Active |
| NCT05129319 | Phase 1 | Completed |
Competing Products
19 competing products in Glabellar Frown Lines
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| AGN-151586 + BOTOX + Placebo | AbbVie | Phase 1 | 29 |
| Placebo + AGN-151586 | AbbVie | Phase 3 | 40 |
| AGN-151586 + Placebo | AbbVie | Phase 3 | 40 |
| AGN-151586 + OnabotulinumtoxinA + Placebo | AbbVie | Phase 1 | 29 |
| AGN-151586 + Placebo | AbbVie | Phase 3 | 40 |
| AGN-151586 | AbbVie | Phase 3 | 40 |
| AGN-151586 + Placebo | AbbVie | Phase 1 | 29 |
| Botulinum toxin type A + Botulinum toxin type A + Placebo + Placebo | Ipsen | Phase 3 | 37 |
| IPN10200 + Placebo | Ipsen | Phase 3 | 44 |
| Botulinum toxin type A + Placebo | Ipsen | Phase 3 | 37 |
| Botulinum toxin type A + Botulinum toxin type A + Placebo | Ipsen | Phase 2 | 32 |
| Botulinum toxin type A + Placebo | Ipsen | Phase 3 | 37 |
| IPN10200 + Placebo | Ipsen | Phase 3 | 44 |
| PrabotulinumtoxinA-Xvfs + OnabotulinumtoxinA + PrabotulinumtoxinA-Xvfs | Evolus | Phase 2 | 25 |
| Botulinum toxin, Type A | Evolus | Phase 3 | 30 |
| DWP-450 (Botulinum purified neurotoxin, Type A) | Evolus | Phase 2 | 25 |
| Botulinum toxin, Type A | Evolus | Phase 3 | 30 |
| Botulinum purified neurotoxin, Type A | Evolus | Phase 2 | 25 |
| prabotulinumtoxinA | Evolus | Phase 1 | 19 |